John P. Reinhart is an accomplished C-suite executive and serial entrepreneur who specializes in Longevity Economy innovation, with nearly two decades of recognition for transformative contributions to healthcare and aging services. As a visionary leader in the intersection of technology, healthcare, and demographic change, he has co-founded multiple ventures and led organizations that address the evolving needs of America's aging population while creating scalable business solutions.

Dr. Loleta Robinson is the President & CEO of Fortis Industries, LLC and a physician entrepreneur and healthcare investment strategist. She is known for her ability to bridge clinical insight with business acumen—advancing innovation, guiding commercialization strategies, and aligning cutting-edge medical solutions with market needs. Throughout her career, Dr. Robinson has held pivotal roles at Thermo Electron Corporation and MedImmune Vaccines, and has served as an Entrepreneur in Residence at Blue Cross Blue Shield of Nebraska and the NIH SEED program. As a trusted advisor to startups, she offers strategic guidance on product development, payer engagement, and market access, with a steadfast commitment to clinical relevance, patient safety, and ethical rigor. She holds an MD from the University of Kansas School of Medicine, an MBA in Health Administration from the University of Colorado–Denver, and a Certificate in Venture Capital Finance from UC Berkeley School of Law. Dr. Robinson’s interdisciplinary expertise positions her at the forefront of healthcare innovation, driving growth and impact in a rapidly evolving landscape.

Dr. Ethel Rubin comes to us with a history of accomplishments in the medical device, corporate ventures and translational medicine industry. Most recently, Dr. Rubin oversaw global investments in commercially strategic studies for Medtronic's catheter ablation business, following leadership roles in clinical strategy and medical affairs for Medtronic CRDM. She has consulted for VCs and other corporate clients, taking the lead on due diligence for investment and M&A efforts through her consulting firm, Innovative BioStrategies, LLC. Ethel was previously Chief Scientific Officer of two Maryland companies, CSA Medical, Inc. and BioFortis, Inc, where she played a key role in technology development and commercialization efforts. A cell and molecular scientist by training, Dr. Rubin's research at The Johns Hopkins School of Medicine Sidney Kimmel Comprehensive Cancer Center elucidated pathways for potential intervention in breast cancer. She earned a PhD in Biochemistry and Biophysics from the University of Rochester School of Medicine and Dentistry and has held business leadership roles in many organizations, including Women In Bio, MIDC, GBTC BioTech Roundtable and the Emerging Technology Center incubator, among others.

John Sullivan is a proven leader in healthcare innovation with extensive experience building, operating, and acquiring market-leading businesses that leverage technology to improve health outcomes, drive operational efficiencies, and reduce healthcare costs. Throughout his career, he has demonstrated exceptional ability to work closely with customers, understand complex market needs, and develop products and services designed for rapid marketplace adoption. His comprehensive background spans multiple healthcare sectors including medical devices, biotechnology, healthcare IT, digital health, consumer health, pharmacy, and supply chain management.

Kwame Ulmer is a distinguished medical technology executive and regulatory strategist with over 20 years of experience navigating the complex intersection of innovation, regulation, and commercialization in healthcare. As Managing Partner of MedTech Impact Partners, a specialized regulatory strategy consulting firm, Kwame has established himself as a trusted advisor to medical device companies seeking to successfully navigate FDA requirements and bring life-changing technologies to market.

Dr. Stephen D. Wolpe is a distinguished biotechnology executive and scientific pioneer with over 30 years of experience in therapeutic and diagnostic development, particularly renowned for his groundbreaking discoveries in immunotherapy and inflammatory mediators. As a discoverer of the chemokine superfamily of inflammatory mediators, Dr. Wolpe has fundamentally shaped our understanding of immune system regulation and hematopoiesis.

Anna Zornosa is a seasoned healthcare entrepreneur and executive with deep expertise in building, scaling, and transforming life sciences companies at the intersection of digital technologies and health. As both a successful CEO and strategic advisor, she brings a unique combination of operational excellence, fundraising acumen, and extensive industry networks to help early-stage companies navigate the complex path from innovation to market success.